In May 1966, Senator Ted Kennedy grilled Harvard psychologist Timothy Leary before a Senate subcommittee about the dangers of LSD. The hearing reflected establishment fears that psychedelics fueled the hippie movement, anti-war protests, and social chaos. Leary defended the drug. Kennedy was unmoved.
Nearly 60 years later, another Kennedy stood in the Oval Office as President Trump signed an executive order to accelerate access to psychedelic-based medical treatments. This time, the ally was Robert F Kennedy Jr, the psychedelics champion within Trump's coalition. Podcaster Joe Rogan joined him in the room, later revealing he had texted the president to push for the order.
The contrast is stark. What once provoked moral panic from the American right now enjoys backing from a warmongering Republican administration and Silicon Valley titans. The shift reflects genuine scientific progress, military and police lobbying, and most crucially, one factor that changes everything: money.
Clinical research has reframed psychedelics as potential treatments for depression, PTSD, and suicidal ideation. Veterans groups have pushed for years to legalize them for trauma recovery. Even law enforcement has begun calling for similar reforms. Conservative communities that once rejected these substances now see therapeutic promise.
But the financial incentive accelerates everything. Forbes predicts the psychedelic mushroom market will exceed $3.3 billion by 2031 following recent drug law reforms. With mental health diagnoses climbing so sharply that 1 billion people worldwide now live with mental disorders, psychedelics could rival the commercial success of Ozempic. Biotech investor Christian Angermayer has described the moment plainly: the industry believes it found "the solution for the biggest problem in healthcare."
The capital is flowing from familiar sources. Peter Thiel backed a psychedelic biotech startup with $125 million in 2020. Google co-founder Sergey Brin invested $15 million in a company developing ibogaine, a West African plant compound, as a traumatic brain injury treatment. The tech oligarchy has mobilized behind the space.
Silicon Valley's enthusiasm traces back further than recent deals. Since the 1960s, California computer scientists have blended psychedelic experimentation with technological innovation as a unified counterculture pursuit. Steve Jobs, Bill Gates, and Sam Altman have all spoken publicly about their own psychedelic use, gradually normalizing what was once fringe. That casual mainstreaming created fertile ground for commercial investment.
The politics remain unusual. Both Democrats and Republicans now support drug policy reform, with blue states like Colorado and Oregon advancing psychedelic therapy fastest. Yet it is Trump's Republican administration partnered with tech capital that is driving federal acceleration. When Trump joked "Can I have some, please?" while signing the ibogaine order, traditional Republicans may have wondered if the room itself had been spiked.
Timothy Leary once urged people to "turn on, tune in, and drop out" of mainstream society. The vision has inverted. Psychedelics are now discussed at Davos forums on "brain capital and human flourishing." The energy has migrated from beatniks to biohackers, from flower power to venture capital. More people may gain access to treatments that genuinely transform lives. But control over that future remains concentrated in very few hands.
Author James Rodriguez: "From dangerous drug to venture opportunity in a generation, psychedelics show how American capitalism co-opts and commercializes even the most transgressive movements."
Comments